The integration of mobile health (mHealth) technologies into decentralized clinical trials (DCTs) may represent a paradigm shift in oncology research, offering innovative solutions to longstanding challenges in clinical trial design and execution. mH...
BACKGROUND: We aimed to develop an actionable and feasible prospective clinical model to estimate toxicity risk to assist chimeric antigen receptor (CAR) T-cell therapy providers with the management of patients with relapsed and/or refractory large B...
The integration of artificial intelligence (AI) chatbots into clinical trials offers a transformative approach to collecting patient-reported outcomes (PROs). Despite the increasing use of AI chatbots for real-time, interactive data gathering, system...
Recent reports have raised concerns about emergent behaviors in next-generation artificial intelligence (AI) models. These systems have been documented selectively adapting their behaviors during testing to falsify experimental outcomes and bypass re...
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factor...
Model-informed drug development (MIDD) methods play critical role to ensure development of efficacious, and safe individualized therapies. The application of artificial intelligence/machine learning (AI/ML) within the field of drug development has ex...
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Apr 14, 2025
The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million people each ye...
Drug discovery before the 20th century often focused on single genes, molecules, cells, or organs, failing to capture the complexity of biological systems. The emergence of protein-protein interaction network studies in 2001 marked a turning point an...
CPT: pharmacometrics & systems pharmacology
Apr 7, 2025
With the recent and evolving regulatory frameworks regarding the usage of Artificial Intelligence (AI) in both drug and medical device development, the differentiation between data derived from observed ('true' or 'real') sources and artificial data ...
BACKGROUND AND OBJECTIVES: Among the participants of Alzheimer disease (AD) treatment trials, 40% do not show cognitive decline over 80 weeks of follow-up. Identifying and excluding these individuals can increase power to detect treatment effects. We...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.